A Retrospective Study Assessing the Persistence on Golimumab as Second Line Biological Therapy in Patients with Spondyloarthritis (Axial Spondyloarthritis and Psoriatic Arthritis)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Golimumab (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Spondylarthritis
Focus Therapeutic Use
Acronyms Go-Beyond

14 Nov 2022 Results of pooled analysis of european prospective observational studies (the GO BEYOND Program), presented at the ACR Convergence 2022
02 Apr 2021 Results evaluating probability of persistence (retention rate of treatment with golimumab, or drug survival) over time and variables associated with higher persistencepublished in the Medicine
13 Jul 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com